Planned delivery or expectant management for late preterm pre-eclampsia: study protocol for a randomised controlled trial (PHOENIX trial)
Authors:
- Lucy C. ChappellLCLucy C. Chappell
- Marcus GreenMGMarcus Green
- Neil MarlowNMNeil Marlow
- Jane SandallJSJane Sandall
- Rachael HunterRachael Hunter
- Stephen RobsonSRStephen Robson
- Ursula BowlerUBUrsula Bowler
- Virginia ChiocchiaVCVirginia Chiocchia
- Pollyanna HardyPHPollyanna Hardy
- Edmund JuszczakEJEdmund Juszczak
- Louise LinsellLLLouise Linsell
- Anna PlaczekAPAnna Placzek
Open Access
- 28 January 2019
- journal article
- research article
- Published by Springer Nature in Trials
- Vol. 20 (1) , 1-13
Abstract
Pre-eclampsia is a pregnancy disorder, characterised by hypertension and multisystem complications in the mother. The adverse outcomes of pre-eclampsia include severe hypertension, stroke, renal and hepatic injury, haemorrhage, fetal growth restriction and even death. The optimal time to instigate delivery to prevent morbidity when pre-eclampsia occurs between 34 and 37 weeks’ gestation, without increasing problems related to infant immaturity or complications, remains unclear. The PHOENIX trial is a non-masked, randomised controlled trial, comparing planned early delivery (with initiation of delivery within 48 h of randomisation) with usual care (expectant management) in women with pre-eclampsia between 34+ 0 and 36+ 6 weeks’ gestation. The primary objectives of the trial are to determine if planned delivery reduces adverse maternal outcomes, without increasing the short-term harm to infants (composite of perinatal deaths or neonatal unit admissions up to infant hospital discharge) or impacting long-term infant neurodevelopmental status at 2 years corrected age (Parent Report of Cognitive Abilities-Revised). Current practice in the UK at the time of trial commencement for management of pre-eclampsia varies by gestation. Previous trials have shown that in women with pre-eclampsia after 37 weeks of gestion, delivery is initiated, as maternal complications are reduced without increasing fetal risks. Prior to 34 weeks of gestation, usual management aims to prolong pregnancy for fetal benefit, unless severe complications occur, necessitating preterm delivery. This trial aims to address the uncertainty for women where the balance of benefits and risks of delivery compared to expectant management are uncertain. Previous trials in this area have been undertaken, but have not provided a definitive answer, and the research question remains active. The results of this trial are expected to influence clinical practice internationally, through direct adoption and by incorporation into guidelines in countries with similar settings. ISRCTN01879376 . Registered on 25 November 2013.Keywords
Funding Information
- National Institute for Health Research (12/25/03)
This publication has 16 references indexed in Scilit:
- Hypertension in PregnancyObstetrics & Gynecology, 2013
- Interventionist versus expectant care for severe pre-eclampsia between 24 and 34 weeks' gestationCochrane Database of Systematic Reviews, 2013
- Reporting and analysis of trials using stratified randomisation in leading medical journals: review and reanalysisBMJ, 2012
- Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)Quality of Life Research, 2011
- Saving Mothers’ Lives: Reviewing maternal deaths to make motherhood safer: 2006–2008BJOG: An International Journal of Obstetrics & Gynaecology, 2011
- Prediction of adverse maternal outcomes in pre-eclampsia: development and validation of the fullPIERS modelThe Lancet, 2011
- Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trialThe Lancet, 2006
- A proposed charter for clinical trial data monitoring committees: helping them to do their job wellThe Lancet, 2005
- A proposed charter for clinical trial data monitoring committees: helping them to do their job wellThe Lancet, 2005
- A 12-Item Short-Form Health SurveyMedical Care, 1996